New Diabetes Drug Retatrutide Shows Promise in Trial
Adults with type 2 diabetes saw greater weight and blood sugar improvements with retatrutide than with Ozempic over 80 weeks.
Updated on Oct. 28, 2026 in Diabetes
Live Poll
Would you switch to a new diabetes medication if clinical trials showed it performed better?
In the phase 3 TRANSCEND-T2D-2 trial of 1,298 adults with type 2 diabetes, retatrutide showed greater improvements in blood sugar control and weight loss compared to Ozempic over 80 weeks. These findings provide new data for adults currently struggling to maintain glycemic control with metformin.
Why it matters
The study offers a potential new treatment path for patients who remain unable to hit glycemic targets despite using foundational therapies like metformin. Understanding how these GLP-1 receptor-based medications compare is critical for future discussions with a primary care physician.
This Phase 3 randomized trial tracked 1,298 adults with type 2 diabetes who were unable to reach glycemic control with metformin, comparing 80-week outcomes across three dosing arms. While efficacy data showed superior HbA1c and weight reductions for retatrutide, full findings remain under peer review.
The details
The trial compared retatrutide against Ozempic by measuring their impact on blood glucose levels and total body weight. Participants were randomly assigned to receive either 9 mg or 12 mg of retatrutide or 2 mg of Ozempic to observe how these treatments affect metabolism over 80 weeks. Discontinuation rates due to adverse events, which included common gastrointestinal issues like nausea and diarrhea, were 4.8% for the 9 mg group, 7.9% for the 12 mg group, and 2.7% for the Ozempic group.
Timeline
80 weeks: Duration of the study treatment period.
Health Landscape
This study follows the precedent established by the SURMOUNT-1 trial in evaluating next-generation weight and diabetes management. It represents a shift in clinical research toward comparing potent new agonists against current standard-of-care weight and glucose management therapies.
If you are currently managing type 2 diabetes and struggling to meet your HbA1c goals with metformin, these findings are worth noting for your next checkup. Discuss with your physician whether emerging therapies align with your long-term health needs and current treatment plan.
The takeaway
Retatrutide demonstrated significant potential for improving weight and blood sugar control in clinical settings, though it remains in the investigative stage. Patients should continue monitoring their current treatment adherence and keep a record of symptoms like nausea to share with their doctor.
Further reading
For more information on current treatment standards, visit the Diabetes section.
Live Poll
Would you switch to a new diabetes medication if clinical trials showed it performed better?
